Clinical Trial

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Study acronym: OVPrecision
Recruiting
View on ClinicalTrials.gov →
Summary
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-06-13; most recent amendment 2026-05-04.
Status change: Not Yet Recruiting → Recruiting 2025-05-12
Trial Details
NCT Number NCT06466382
Lead Sponsor Swiss GO Trial Group
Collaborators: Tumor Profiler Center Switzerland
Conditions Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Ovarian Endometrioid Carcinoma, High-grade Serous Ovarian Carcinoma (HGSOC)
Enrollment 60 participants
Start Date 2025-03-31
Primary Completion 2027-03 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-05